Softdeal Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-07-2024
- Paid Up Capital ₹ 0.10 M
as on 16-07-2024
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -13.53%
(FY 2023)
- Profit -7.16%
(FY 2023)
- Ebitda -12.57%
(FY 2023)
- Net Worth 90.81%
(FY 2023)
- Total Assets 24.84%
(FY 2023)
About Softdeal Pharmaceutical
The Corporate was formerly known as Softdeal Trading Company Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prince Elias, Rakeshchandra Sinha, and Kedar Senapati serve as directors at the Company.
- CIN/LLPIN
U51900MH2006PTC159237
- Company No.
159237
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jan 2006
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Softdeal Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakeshchandra Sinha  | Director | 19-Apr-2019 | Current |
| Prince Elias | Additional Director | 20-Feb-2024 | Current |
| Kedar Senapati | Director | 21-Feb-2022 | Current |
Financial Performance of Softdeal Pharmaceutical.
Softdeal Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.53% decrease. The company also saw a slight decrease in profitability, with a 7.16% decrease in profit. The company's net worth Soared by an impressive increase of 90.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Softdeal Pharmaceutical?
In 2022, Softdeal Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sun Pharmaceutical Medicare LimitedActive 7 years 11 monthsPrince Elias, Rakeshchandra Sinha and 1 more are mutual person
Pharmarack Technologies Private LimitedActive 9 years 3 monthsRakeshchandra Sinha is a mutual person
Caraco Pharmaceuticals Private LimitedActive 12 years 11 monthsPrince Elias and Rakeshchandra Sinha are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Softdeal Pharmaceutical?
Softdeal Pharmaceutical has a workforce of 78 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Softdeal Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Softdeal Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
